Richard D. Carvajal
Experienced in Fibrosarcoma

Dr. Richard D. Carvajal

Oncology
450 Lakeville Road, Entrance B, 
Lake Success, NY 
On Staff At
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Experienced in Fibrosarcoma
450 Lakeville Road, Entrance B, 
Lake Success, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Richard Carvajal is an Oncologist in Lake Success, New York. Dr. Carvajal is rated as an Experienced provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, Melanoma, and Tissue Biopsy.

His clinical research consists of co-authoring 218 peer reviewed articles and participating in 29 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Fibrosarcoma.

Graduate Institution
New York University School Of Medicine
Residency
University of Michigan Medical Center
Specialties
Oncology
Licenses
Internal Medicine in NY
Board Certifications
American Board Of Internal Medicine/Medical Oncology
Fellowships
Memorial Sloan-Kettering Cancer Center
Hospital Affiliations
Phelps Hospital
Peconic Bay Medical Center
Huntington Hospital
North Shore University Hospital
Long Island Jewish Medical Center
North Shore University Hospital Syosset
Glen Cove Hospital
Hofstra/Northwell School Of Medicine/Nursing
Lenox Hill Hospital
Northern Westchester Hospital
Plainview Hospital
Long Island Jewish Valley Stream
South Shore University Hospital
Staten Island University Hospital
Cancer Institute
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Northwell Health Center for Advanced Medicine, RJ Zuckerberg Cancer Center
450 Lakeville Road, Entrance B, Lake Success, NY 11042
Other Locations
Northwell Health Physician Partners Medical Oncology at MEETH
210 East 64th Street, 4th Floor, New York, NY 10065

Additional Areas of Focus

Dr. Carvajal has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Uveal Melanoma
Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Enrollment Status: Recruiting
Publish Date: August 26, 2025
Intervention Type: Drug
Study Drugs: Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Regorafenib, Olaparib, Pembrolizumab, Nivolumab and Ipilimumab, Abemaciclib, Afatinib, Talazoparib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Entrectinib, Larotrectinib, Tucatinib plus Trastuzumab Subcutaneous (SC)
Study Phase: Phase 2
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: August 15, 2025
Intervention Type: Drug
Study Drugs: BCA101, Pembrolizumab
Study Phase: Phase 1
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma
A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Other, Drug
Study Drug: Vorinostat
Study Phase: Phase 2
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Biological, Other, Drug
Study Drugs: Dabrafenib, Navitoclax, Trametinib
Study Phase: Phase 1/Phase 2
A Prospective Natural History Study in Uveal Melanoma
A Prospective Natural History Study in Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 22, 2025
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Biological
Study Drugs: Enoblituzumab, Pembrolizumab, MGA012 Anti-PD-1 Antibody
Study Phase: Phase 1
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Biological, Drug
Study Drugs: LGK974, PDR001
Study Phase: Phase 1
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Cetuximab
Study Phase: Phase 2
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
Enrollment Status: Completed
Publish Date: February 04, 2025
A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination With AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients With Advanced Cancer
A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination With AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients With Advanced Cancer
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drugs: AGEN2373, Botensilimab
Study Phase: Phase 1
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Enrollment Status: Terminated
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Enrollment Status: Completed
Publish Date: December 06, 2023
Intervention Type: Drug
Study Drug: Crizotinib
Study Phase: Phase 2
A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors
A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification
A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: September 08, 2023
Intervention Type: Drug, Procedure
Study Drugs: Pegylated arginine deiminase, Gemcitabine, Docetaxel
Study Phase: Phase 2
Multi-Center Phase Ib Study of Intermittent Dosing of the MEK Inhibitor, Selumetinib, in Patients With Advanced Uveal Melanoma Not Previously Treated With a MEK Inhibitor
Multi-Center Phase Ib Study of Intermittent Dosing of the MEK Inhibitor, Selumetinib, in Patients With Advanced Uveal Melanoma Not Previously Treated With a MEK Inhibitor
Enrollment Status: Completed
Publish Date: August 31, 2023
Intervention Type: Drug
Study Drug: Selumetinib
Study Phase: Phase 1
Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination With BYL719, a PI3Kα Inhibitor, in Patients With Metastatic Uveal Melanoma
Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination With BYL719, a PI3Kα Inhibitor, in Patients With Metastatic Uveal Melanoma
Enrollment Status: Completed
Publish Date: August 15, 2023
Intervention Type: Drug
Study Drugs: AEB071, BYL719
Study Phase: Phase 1
Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular Melanoma
Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular Melanoma
Enrollment Status: Unknown
Publish Date: April 11, 2023
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: IMCgp100
Study Phase: Phase 1/Phase 2
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors
A Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Enrollment Status: Completed
Publish Date: August 30, 2021
Intervention Type: Drug
Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab
Study Phase: Phase 1
View 25 Less Clinical Trials

218 Total Publications

Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504.
Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504.
Journal: Cancers
Published: August 08, 2025
Similar Doctors
Elite in Fibrosarcoma
Dr. William D. Tap
Hematology Oncology | Hematology | Oncology
Elite in Fibrosarcoma
Dr. William D. Tap
Hematology Oncology | Hematology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
 (13.7 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

William Tap is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Tap is rated as an Elite provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Tissue Biopsy, and Liver Embolization.

Elite in Fibrosarcoma
Dr. Sandra Dangelo
Oncology
Elite in Fibrosarcoma
Dr. Sandra Dangelo
Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (13.0 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sandra Dangelo is an Oncologist in New York, New York. Dr. Dangelo is rated as an Elite provider by MediFind in the treatment of Fibrosarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Merkel Cell Carcinoma, Liposarcoma, and Liver Embolization.

Distinguished in Fibrosarcoma
Dr. Sujana Movva
Oncology | Hematology Oncology | Hematology
Distinguished in Fibrosarcoma
Dr. Sujana Movva
Oncology | Hematology Oncology | Hematology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (13.0 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sujana Movva is an Oncologist and a Hematologist Oncology provider in New York, New York. Dr. Movva is rated as an Elite provider by MediFind in the treatment of Fibrosarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Gastrointestinal Stromal Tumor, Pancreaticoduodenectomy, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carvajal's expertise for a condition
ConditionClose
    View All 46 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile